Detalhe da pesquisa
1.
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
Immunity
; 44(3): 609-621, 2016 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26944201
2.
Role of PD-1 during effector CD8 T cell differentiation.
Proc Natl Acad Sci U S A
; 115(18): 4749-4754, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29654146
3.
Chemotherapy Combines Effectively with Anti-PD-L1 Treatment and Can Augment Antitumor Responses.
J Immunol
; 201(8): 2273-2286, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30209192
4.
Autoimmunity linked protein phosphatase PTPN22 as a target for cancer immunotherapy.
J Immunother Cancer
; 8(2)2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33127657
5.
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer.
Nat Cancer
; 1(7): 681-691, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35122038
6.
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.
J Clin Invest
; 116(5): 1310-6, 2006 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-16670770
7.
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.
Science
; 355(6332): 1428-1433, 2017 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28280247
8.
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
Nat Commun
; 8: 14572, 2017 02 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-28220772
9.
IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells.
Immunity
; 16(6): 779-90, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12121660
10.
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.
J Immunol
; 168(11): 5699-708, 2002 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12023369